Vermillion Q4 Loss Widens - Quick Facts

(RTTNews) - Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, said fourth-quarter net loss widened to $4.1 million or $0.11 per share from $1.8 million or $0.07 per share in the same year-ago quarter.

Total revenue in the fourth quarter of 2014 was $1.6 million, nearly flat with last year. Product revenue comprised of $214,000 from 4,474 OVA1 tests performed and $1.2 million from the royalty on 16,563 OVA1 tests reported by Quest Diagnostics as resolved in 2014.

Total operating expenses increased to $5.2 million from $3.34 million, due to higher Sales and marketing as well as General and administrative expenses.